🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesGot off metformin for the first time in 8 years - crying happy tears — 12 month update

Got off metformin for the first time in 8 years - crying happy tears — 12 month update

DataDave Fri, Feb 13, 2026 at 1:29 AM 5 replies 851 viewsPage 1 of 1
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Feb 13, 2026 at 1:29 AM#1

Writing this once so I can stop repeating it across threads. It is about glycaemic control, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very little. The improvement on this class comes from two directions — direct glucose-dependent insulin secretion and glucagon suppression, plus the indirect effect of weight loss on insulin sensitivity — and the second continues after the first has plateaued.

The condition it depends on

The caveat that HbA1c is unreliable in anaemia, haemoglobinopathies and recent blood loss, all of which are commoner than people assume. If it disagrees with fasting glucose or a CGM, that is worth chasing.

The practical version

Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.

What I am not sure about

What I actually want to know is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner. I would rather have one careful answer than five confident ones.

— DataDave · corrections welcome and will be edited into this post with credit
22 17VendorMark, COA_Karl, MikeFit_NJ and 19 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Feb 13, 2026 at 1:36 AM#2
DataDave said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1281029286
Insulin (fasting)241686
HOMA-IR4.52.92.01.2
Uric Acid7.66.85.94.9

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.

21 16KristenIndy, MarkLI_maint, Dr.PeteFamMed and 18 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Feb 13, 2026 at 1:43 AM#3
DataDave said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

After 12 months: periods became regular for the first time in ever, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my hormonal symptoms have almost completely resolved.

GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.

Last edited: Feb 13, 2026 at 2:43 AM
20 15mark_tokyo, hans_munich, jason_sac26 and 17 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Feb 13, 2026 at 1:50 AM#4
Dr.RaviCardio said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

19 14tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 16 others
Reply Quote Save Share Report
carl_compliance
Member
234
1,123
Nov 2024
Raleigh, NC
Feb 13, 2026 at 2:27 AM#5
VendorMark said:
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone: Test Baseline Month 3 Month 6 Month 12…

This matches mine closely enough to be worth saying so out loud.

18 13dave_SLC, FDA_TrackerJim, ricardo_MIA and 15 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register